PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for BIIB (Biogen) from 1991 to Jul 12 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biogen stock (BIIB) PE ratio as of Jul 12 2020 is 8.61. More Details

Biogen PE Ratio (TTM) Chart

EMBED

Biogen PE Ratio (TTM) Historical Data

Total 1246
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biogen PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-07-128.6 2020-05-1110.1
2020-07-108.6 2020-05-089.7
2020-07-098.6 2020-05-079.7
2020-07-088.7 2020-05-069.5
2020-07-078.3 2020-05-059.4
2020-07-068.3 2020-05-049.2
2020-07-038.2 2020-05-019.1
2020-07-028.2 2020-04-309.2
2020-07-018.2 2020-04-299.4
2020-06-308.3 2020-04-289.4
2020-06-298.0 2020-04-279.4
2020-06-268.0 2020-04-249.2
2020-06-258.1 2020-04-239.0
2020-06-248.1 2020-04-229.2
2020-06-238.3 2020-04-2110.2
2020-06-228.2 2020-04-2010.5
2020-06-198.4 2020-04-1710.6
2020-06-188.0 2020-04-1610.4
2020-06-178.7 2020-04-1510.1
2020-06-168.7 2020-04-1410.3
2020-06-158.6 2020-04-1310.0
2020-06-128.6 2020-04-109.9
2020-06-118.7 2020-04-099.9
2020-06-109.1 2020-04-089.8
2020-06-099.1 2020-04-079.3
2020-06-089.3 2020-04-069.6
2020-06-059.5 2020-04-039.3
2020-06-049.3 2020-04-029.4
2020-06-039.3 2020-04-019.1
2020-06-029.4 2020-03-319.8
2020-06-019.3 2020-03-309.8
2020-05-299.5 2020-03-279.4
2020-05-289.3 2020-03-269.7
2020-05-279.3 2020-03-259.1
2020-05-269.1 2020-03-248.8
2020-05-259.4 2020-03-238.6
2020-05-229.4 2020-03-208.9
2020-05-219.4 2020-03-199.2
2020-05-209.6 2020-03-189.5
2020-05-199.6 2020-03-179.7
2020-05-189.8 2020-03-169.0
2020-05-159.8 2020-03-139.7
2020-05-149.8 2020-03-128.5
2020-05-139.7 2020-03-119.4
2020-05-129.9 2020-03-109.7

Biogen PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.